A Phase I Study To Evaluate The Safety And Tolerability of JSP191 For Hematopoietic Cell Transplantation Conditioning To Achieve Engraftment And Immune Reconstitution In Subjects With SCID
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Briquilimab (Primary)
- Indications Immunodeficiency disorders; Immunological disorders
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Jasper Therapeutics
- 31 Mar 2022 According to a Jasper Therapeutics media release, updated data from this trial will be presented at the 2022 Clinical Immunology Society (CIS) Annual Meeting
- 14 Dec 2021 Results of an analysis of a data supporting a recommended phase 2 dose (RP2D) of JSP191 that achieves donor HSC engraftment predictive of clinically meaningful lymphocyte reconstitution presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 08 Dec 2021 Results presented in a Jasper Therapeutics media release.